Zanzalintinib Anaplastic Thyroid Cancer Trial: NCT07470489
Phase 2 trial NCT07470489 pairs zanzalintinib with cemiplimab in BRAF wild-type anaplastic thyroid cancer; ChEMBL, ClinicalTrials.gov and DepMap data inside.
BioQ Blog
Every BioQ post about cemiplimab: real search results, sources and the query to repeat it.
Phase 2 trial NCT07470489 pairs zanzalintinib with cemiplimab in BRAF wild-type anaplastic thyroid cancer; ChEMBL, ClinicalTrials.gov and DepMap data inside.